References

Unresolved reference

External reference

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study

10.1016/s1473-3099(14)70847-3 · 2014 · External reference

Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services

10.1001/jamainternmed.2015.4683 · 2016 · External reference

Redefining Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis Failures

10.1093/cid/cix593 · 2017 · External reference

Getting to Zero San Francisco: A Collective Impact Approach

10.1097/qai.0000000000002200 · 2019 · External reference

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

10.1038/nature12746 · 2013 · External reference

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

10.1126/scitranslmed.aao4235 · 2017 · External reference

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

10.1016/j.chom.2019.08.014 · 2019 · External reference

Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus

10.1097/qad.0000000000002934 · 2021 · External reference

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

10.1038/nature14411 · 2015 · External reference

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

10.1038/nature18929 · 2016 · External reference

Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic

10.1038/s41591-019-0412-8 · 2019 · External reference

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

10.1038/72309 · 2000 · External reference

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

10.1038/nature11604 · 2012 · External reference

Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo

10.1093/infdis/jiw203 · 2016 · External reference

VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice

10.1007/s00705-016-2942-4 · 2016 · External reference

Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice

10.1080/19420862.2020.1845908 · 2020 · External reference

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

10.1038/nm.4268 · 2017 · External reference

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

10.1126/scitranslmed.aad5752 · 2015 · External reference

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

10.1111/cei.12692 · 2015 · External reference

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

10.1038/s41591-018-0186-4 · 2018 · External reference

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

10.1056/nejmoa1608243 · 2016 · External reference

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

10.1056/nejmoa2031738 · 2021 · External reference

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

10.1371/journal.ppat.1005520 · 2016 · External reference

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials

10.1371/journal.ppat.1011469 · 2023 · External reference

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

10.1371/journal.ppat.1005520 · 2016 · External reference

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes

10.1128/jvi.03136-14 · 2015 · External reference

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

10.1371/journal.ppat.1005742 · 2016 · External reference

Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities

10.1186/s12977-021-00556-2 · 2021 · External reference

Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level

10.1038/nm.2203 · 2010 · External reference

Antibody neutralization and escape by HIV-1

10.1038/nature01470 · 2003 · External reference

Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection

10.1128/jvi.01839-06 · 2007 · External reference

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape

10.1038/nm.2985 · 2012 · External reference

Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection

10.1128/jvi.01270-22 · 2022 · External reference

Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection

10.1016/j.virol.2020.03.003 · 2020 · External reference

Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure

10.3389/fimmu.2021.757400 · 2021 · External reference

Cell-to-cell contact results in a selective translocation of maternal human immunodeficiency virus type 1 quasispecies across a trophoblastic barrier by both transcytosis and infection

10.1128/jvi.75.10.4780-4791.2001 · 2001 · External reference

Proteasome-independent degradation of HIV-1 in naturally non-permissive human placental trophoblast cells

10.1186/1742-4690-6-46 · 2009 · External reference

Endogenous Retroviral Envelope Syncytin Induces HIV-1 Spreading and Establishes HIV Reservoirs in Placenta

10.1016/j.celrep.2020.03.016 · 2020 · External reference

Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers

10.1371/journal.ppat.1009478 · 2021 · External reference

Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission is strain- and epitope-dependent

2015 · External reference

Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies

10.1371/journal.ppat.1002634 · 2012 · External reference

Early development of broadly neutralizing antibodies in HIV-1-infected infants

10.1038/nm.3565 · 2014 · External reference

Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection

10.1126/scitranslmed.aag1048 · 2016 · External reference

HIV-1 subtype C-infected children with exceptional neutralization breadth exhibit polyclonal responses targeting known epitopes

10.1128/jvi.00878-18 · 2018 · External reference

Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study

2018 · External reference

A fresh approach: Combining basic science and social good

10.1126/sciimmunol.aau2798 · 2018 · External reference

High-frequency failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal NON-ADHERENCE

10.1016/j.eclinm.2020.100344 · 2020 · External reference

Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma

10.1371/journal.ppat.1006944 · 2018 · External reference

A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings

10.1128/jcm.00382-20 · 2020 · External reference

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

10.1126/science.1093137 · 2004 · External reference

HIV transmission

2012 · External reference

The HIV-1 transmission bottleneck

10.1186/s12977-017-0343-8 · 2017 · External reference

10.1126/science.1254031

10.1126/science.1254031 · 2014 · External reference

Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1

10.1128/jvi.69.12.8118-8122.1995 · 1995 · External reference

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

10.1073/pnas.0802203105 · 2008 · External reference

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection

10.1084/jem.20090378 · 2009 · External reference

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors

10.1128/jvi.00758-09 · 2009 · External reference

Measuring HIV neutralization in a luciferase reporter gene assay

10.1007/978-1-59745-170-3_26 · 2009 · External reference

Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies

10.1084/jem.20130221 · 2013 · External reference

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design

10.1016/j.chom.2018.12.001 · 2019 · External reference

New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency

10.1128/jvi.01791-15 · 2016 · External reference

Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV

2014 · External reference

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

10.1128/jvi.78.19.10724-10737.2004 · 2004 · External reference

Potent and broad HIV-neutralizing antibodies in memory B cells and plasma

10.1126/sciimmunol.aal2200 · 2017 · External reference

Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers

10.1016/j.immuni.2014.04.008 · 2014 · External reference

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

10.1371/journal.ppat.1005742 · 2016 · External reference

Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk

10.1128/jvi.02422-16 · 2017 · External reference

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants

10.1128/mbio.00176-20 · 2020 · External reference

Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission

10.1172/jci81593 · 2015 · External reference

Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures

10.1186/s12977-017-0331-z · 2017 · External reference

Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant

10.1128/jvi.80.2.835-844.2006 · 2006 · External reference